Bioerodible film for ophthalmic drug delivery

Details Bioerodible film for ophthalmic drug delivery Bioerodible film for ophthalmic drug delivery

2003-06-30

2011-12-27

Hartley, Michael G (Department: 1618)

Drug, bio-affecting and body treating compositions

Preparations characterized by special physical form

Implant or insert

Reexamination Certificate

active

08084054

ABSTRACT:
Drug delivery film compositions containing a combination of a water-soluble, film-forming polymers and a fatty acid glyceride or ester are suitable for delivering ophthalmic drugs.

REFERENCES:
patent: 4344968 (1982-08-01), Aoda et al.
patent: 4786495 (1988-11-01), Bird et al.
patent: 4865846 (1989-09-01), Kaufman
patent: 4880636 (1989-11-01), Franz
patent: 5362478 (1994-11-01), Desai et al.
patent: 5433951 (1995-07-01), Serajuddin et al.
patent: 5439686 (1995-08-01), Desai et al.
patent: 5473055 (1995-12-01), Mongelli et al.
patent: 5484608 (1996-01-01), Rudnic et al.
patent: 5498421 (1996-03-01), Grinstaff et al.
patent: 5504102 (1996-04-01), Agharkar et al.
patent: 5569720 (1996-10-01), Mongelli et al.
patent: 5614549 (1997-03-01), Greenwald et al.
patent: 5626862 (1997-05-01), Brem et al.
patent: 5651986 (1997-07-01), Brem et al.
patent: 5665382 (1997-09-01), Grinstaff et al.
patent: 5716981 (1998-02-01), Hunter et al.
patent: 5719265 (1998-02-01), Mongelli et al.
patent: 5736152 (1998-04-01), Dunn
patent: 5783178 (1998-07-01), Kabanov et al.
patent: 5886026 (1999-03-01), Hunter et al.
patent: 5888493 (1999-03-01), Sawaya
patent: 5916596 (1999-06-01), Desai et al.
patent: 5994341 (1999-11-01), Hunter et al.
patent: 6004573 (1999-12-01), Rathi et al.
patent: 6017948 (2000-01-01), Rubinfeld et al.
patent: 6063116 (2000-05-01), Kelleher
patent: 6096331 (2000-08-01), Desai et al.
patent: 6117425 (2000-09-01), MacPhee et al.
patent: 6146659 (2000-11-01), Rahman
patent: 6306120 (2001-10-01), Tan
patent: 6369116 (2002-04-01), Wong et al.
patent: 6375963 (2002-04-01), Repka et al.
patent: 6491948 (2002-12-01), Buchholz et al.
patent: 6525214 (2003-02-01), Armitage et al.
patent: 2002/0192280 (2002-12-01), Hunter et al.
patent: 2004/0058313 (2004-03-01), Abreu
patent: 2086218 (1997-08-01), None
patent: WO 97/45105 (1997-12-01), None
patent: WO 99/00113 (1999-01-01), None
patent: WO 99/21908 (1999-05-01), None
patent: WO 00/64437 (2000-11-01), None
patent: WO 01/89522 (2001-11-01), None
Taxol (Neil Edwards) Feb. 1996. Retrieved from the world wide web at www.chm.bris.ac.uk/motm/taxol/taxol.htm on May 3, 2006.
Triacetin disclosure, downloaded from the world wide web at www.chemicalland21.com/industrialchem/plasticizer/TRIACETIN.hgm on Jan. 22, 2007.
Cavalli et al. “Preparation and characterizatin of solid lipid nanospheres containing paclitaxel” European Journal fo Pharmaceutical Sciences 10 (2000) 305-309.
Polyoxyethylene (40) Stearate disclosure, downloaded from the world wide web on Apr. 7, 2008.
Polyoxyethylene (40) Stearate MSDS, downloaded from the world wide web on Apr. 7, 2008.
Hamdani et al., “Physical and thermal characterisation of Precirol® and Comptirol® as lipophlic glycerides used for the preparation of controlled-release matrix pellets,”International J. of Pharmaceutics,vol. 260, pp. 47-57 (2003).
Blandford et al., “Subconjunctival Sustained Release 5-Fluorouracil,”Investigative Ophthalmology&Visual Science,vol. 33(12), pp. 3430-3435 (1992).
Borisuth et al., “The Risk Profile of Glaucoma Filtration Surgery,”Current Opin. Ophthalmology,vol. 10; pp. 112-116 (1999).
Chang et al., “Basic Science and Clinical Aspects of Wound Healing in Glaucoma Filtering Surgery,”J. of Ocular Pharmacology,vol. 14(1), pp. 75-95 (1998).
Charles et al., “Use of Bioerodible Polymers Impregnated with Mitomycin in Glaucoma Filtration Surgery in Rabbits,”Ophthalmology,vol. 98(4), pp. 503-508 (1991).
Daniels et al., “Taxol Treatemtn of Experimental Proliferative Vitreoretinopathy,”Graefe's Archive Clin. Exp. Ophthalmology,vol. 228, pp. 513-516 (1990).
Dukes et al., “The Use of Daunorubicin-Impregnated Bioerodible Polymers in Glaucoma Filtration Surgery in the Rabbit Model,” Investigative Ophthalmology & Visual Science, vol. 33, p. 1391 (1992).
Greenfield et al., “Endophthalmitis After Filtering Surgery with Mitomycin,”Archives Ophthalmology,vol. 114, pp. 943-949 (1996).
Jampel et al., Filtration Surgery in the Glaucomatous Non-Human Primate Using Polyanhydride Disks Containing Fluoroudine (FUR),Investigative Ophthalmology&Visual Science,vol. 30, p. 417 (1989).
Jampel et al., “Glaucoma Filtration Surgery in Monkeys Using 5-Fluorouridine in Polyanhydride Disks,”Archives of Ophthalmology,vol. 108; pp. 430-435 (1990).
Jampel et al., “Glaucoma Filtration Surgery in Nonhuman Primates Using Taxol and Etoposide in Polyanhydride Carriers,”Investigative Ophthalmology&Vis. Science,vol. 34(11), pp. 3076-3083 (1993).
Jampel et al., “Impact of Adjuvant Chemotherapy on Glaucoma Filtration Surgery,”J. of Glaucoma,vol. 2; pp. 58-63 (1993).
Jampel et al., “In Vitro Release of Hydrophobic Drugs from Polyanhydride Disks,”Ophthalmic Surgery,vol. 22(11), pp. 676-680 (1991).
Jampel et al, “The Effect of Paclitaxel Powder on Glaucoma Filtration Surgery in Rabbits,”J. of Glaucoma,vol. 7, pp. 170-177 (1998).
Lanigan et al., “Single Intraoperative Applications of 5-fluorouracil during Filtration Surgery: Early Results,”British J. of Ophthalmology,vol. 78, pp. 33-37 (1994).
Lee et al., “Effects of Cytosine Arabinoside-Impregnated Bioerodible Polymers on Glaucoma Filtration Surgery in Rabbits,”J. of Glaucoma,vol. 2; pp. 96-100 (1993).
Lee et al., “Glaucoma Filtration Surgery in Rabbits Using Bioerodible Polymers and 5-Fluorouracil,”Ophthalmology,vol. 94(12); pp. 1523-1530 (1987).
Lee et al, “The Use of Bioerodible Polymers and 5-Fluorouracil in Glaucoma Filtration Surgery,”Investigative Ophthalmology&Visual Science,vol. 29 (11); pp. 1692-1697 (1998).
Park et al., “Biodegradable Polyanhydride Devices of Cefazolin Sodium, Bupivacaine, and Taxol for Local and Drug Delivery: Preparation, and Kinetics and Mechanism of In Vitro Release,”J. Control Release,vol. 52, pp. 179-189 (1998).
Rabowsky et al., “The Use of Bioerodible Polymers and Daunorubicin in Glaucoma Filtration Surgery,”Ophthalmology,vol. 103(5); pp. 800-807 (1996).
Robin et al., “A Long-Term Dose-Response Study of Mitomycin in Glaucoma Filtration Surgery,”Archives Ophthalmology,vol. 115, pp. 969-974 (1997).
Smith et al., “Drainage Tube Implantation with Intraoperative Mitomycin-C Application,”Invest. Oph.&Vis. Science,vol. 34(4), p. 731 (1993).
Spaeth et al., “Argon Laser Trabeculoplasty Controls One Third of Cases of Progressive, Uncontrolled, Open Angle Glaucoma for 5 Years,”Archives Ophthalmology,Vol. 110, pp. 491-494 (1992).
Uppal et al., “Pharmacokinetics of Etoposide Delivery by a Bioerodible Drug Carrier Implanted at Glaucoma Surgery,”J. of Ocular Pharmacology,vol. 10(2), pp. 471-479 (1994).
Wilkins et al., “Antimetabolites,”Seminars in Ophthalmology,vol. 12(3), pp. 143-151 (1997).
WuDunn et al., “Combined Penetrating Keratoplasty and Trabeculectomy with Mitomycin C,”Ophthalmology,vol. 106(2), pp. 396-400n(1999).
Deshpande et al., “Bioerodible Polymers for Ocular Drug Delivery,”Critical Reviews in Therapeutic Drug Carrier Systems,vol. 15(4); pp. 381-420 (1998).
Hatefi et al., “Biodegradable injectable in situ forming drug delivery systems,”J. of Controlled Release,vol. 80; pp. 9-28 (2002).

Affiliated with

Also associated with

Rating

Bioerodible film for ophthalmic drug delivery does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Bioerodible film for ophthalmic drug delivery, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Bioerodible film for ophthalmic drug delivery will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4267746